1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Lundbeck’s CNS Investments Are Delivering Returns

 
• By Jessica Merrill

The Danish company’s top line grew by 14% in 2024, driven by strong growth of brands like Rexulti, Brintellix and Vyepti, with continued growth expected.

(Shutterstock)
Key Takeaways

Lundbeck reported 14% revenue growth in 2024 on the strength of four drugs for CNS disorders.

Rexulti, in particular, is expected to be a continued growth-driver, driven by sales in agitation associated with Alzheimer’s and potentially expansion into PTSD.

Two pivotal trials are enrolling now for bexicaserin, the 5HT2C agonist Lundbeck acquired last year with Longboard Pharmaceuticals.

H. Lundbeck is squarely focused on central nervous system disorders, arguably one of the most challenging areas of drug development, but the small specialty pharma is showing that investments in...

The company’s 2024 financial results released on 5 February showed strong revenue and adjusted earnings growth powered by strategic brands including: Rexulti (brexpiprazole) for depression, schizophrenia and agitation associated with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Strategy

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.